Citation: Deyin Guo. Old Weapon for New Enemy: Drug Repurposing for Treatment of Newly Emerging Viral Diseases .VIROLOGICA SINICA, 2020, 35(3) : 253-255.  http://dx.doi.org/10.1007/s12250-020-00204-7

Old Weapon for New Enemy: Drug Repurposing for Treatment of Newly Emerging Viral Diseases

  • Corresponding author: Deyin Guo, guodeyin@mail.sysu.edu.cn, ORCID: http://orcid.org/0000-0002-8297-0814
  • Received Date: 29 January 2020
    Accepted Date: 31 January 2020
    Published Date: 11 February 2020
    Available online: 01 June 2020
  • In December 2019, a dozen of patients with unusual pneumonia were hospitalized in Wuhan in central China, and the causative agent was identified as a new type of coronavirus (Zhu et al. 2020; Huang et al. 2020). The new virus was temporarily named as 2019 novel coronavirus (2019-nCoV) by the World Health Organization (WHO). As of January 29, 2020, 7736 confirmed cases of 2019-nCoV infection with 170 deaths were reported in China, and additional 77 cases in other 16 countries (National Health Commission of the People's Republic of China 2020; WHO 2020c). Since the emerging viruses are previously unknown pathogens, there are no specific and effective drugs available. Therefore, there is an urgent need for antiviral treatment in fighting the emerging viral diseases. However, the development of antiviral drugs is time- and resource-consuming, and thus repurposing of existing drugs to treat emerging viral diseases represents one of efficient strategies for drug development.

  • 加载中
    1. Chattopadhyay R, Mahajan B, Kumar S (2007) Assessment of safety of the major antimalarial drugs. Expert Opin Drug Saf 6:505–521
        doi: 10.1517/14740338.6.5.505

    2. García-Serradilla M, Risco C, Pacheco B (2019) Drug repurposing for new, efficient, broad spectrum antivirals. Virus Res 264:22–31
        doi: 10.1016/j.virusres.2019.02.011

    3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. https://doi.org/10.1016/S0140-6736(20)30183-5
        doi: 10.1016/S0140-6736(20)30183-5

    4. Lo MK, Jordan R, Arvey A, Sudhamsu J, Shrivastava-Ranjan P, Hotard AL, Flint M, McMullan LK, Siegel D, Clarke MO, Mackman RL, Hui HC, Perron M, Ray AS, Cihlar T, Nichol ST, Spiropoulou CF (2017) GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci Rep 7:43395
        doi: 10.1038/srep43395

    5. National Health Commission of the People's Republic of China (2020) http://www.nhc.gov.cn/xcs/yqfkdt/202001/e71bd2e7a0824ca69f87bbf1bef2a3c9.shtml

    6. Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF (2015) Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 23:231–269
        doi: 10.1007/s10787-015-0239-y

    7. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R (2003) Effects of chloroquine on viral infections: an old drug against today's diseases. Lancet Infect Dis 3(11):722–727
        doi: 10.1016/S1473-3099(03)00806-5

    8. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I, Bannister R, Park Y, Babusis D, Clarke MO, Mackman RL, Spahn JE, Palmiotti CA, Siegel D, Ray AS, Cihlar T, Jordan R, Denison MR, Baric RS (2017) Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Trans Med. https://doi.org/10.1126/scitranslmed.aal3653
        doi: 10.1126/scitranslmed.aal3653

    9. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi ZL, Hu Z, Zhong W, Xiao G (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. https://doi.org/10.1038/s41422-020-0282-0
        doi: 10.1038/s41422-020-0282-0

    10. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC et al (2016) Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531:381–385
        doi: 10.1038/nature17180

    11. World Health Organization (WHO) (2020a) https://www.who.int/csr/sars/en/. Accessed 29 Jan 2020

    12. World Health Organization (WHO) (2020b) https://www.who.int/emergencies/mers-cov/en/. Accessed 29 Jan 2020

    13. World Health Organization (WHO) (2020c) https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200129-sitrep-9-ncov-v2.pdf?sfvrsn=e2c8915_2. Accessed 29 Jan 2020

    14. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W (2020) China Novel Coronavirus Investigating and Research Team (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. https://doi.org/10.1056/NEJMoa2001017
        doi: 10.1056/NEJMoa2001017

  • 加载中

Article Metrics

Article views(7124) PDF downloads(85) Cited by()

Related
Proportional views

    Old Weapon for New Enemy: Drug Repurposing for Treatment of Newly Emerging Viral Diseases

      Corresponding author: Deyin Guo, guodeyin@mail.sysu.edu.cn
    • 1. The Centre for Infection and Immunity Studies, School of Medicine, Sun Yat-sen University, Guangzhou 510080, China

    Abstract: In December 2019, a dozen of patients with unusual pneumonia were hospitalized in Wuhan in central China, and the causative agent was identified as a new type of coronavirus (Zhu et al. 2020; Huang et al. 2020). The new virus was temporarily named as 2019 novel coronavirus (2019-nCoV) by the World Health Organization (WHO). As of January 29, 2020, 7736 confirmed cases of 2019-nCoV infection with 170 deaths were reported in China, and additional 77 cases in other 16 countries (National Health Commission of the People's Republic of China 2020; WHO 2020c). Since the emerging viruses are previously unknown pathogens, there are no specific and effective drugs available. Therefore, there is an urgent need for antiviral treatment in fighting the emerging viral diseases. However, the development of antiviral drugs is time- and resource-consuming, and thus repurposing of existing drugs to treat emerging viral diseases represents one of efficient strategies for drug development.